History

NanoCor Therapeutics, Inc. (Chapel Hill, NC) is a biotechnology company focused on the development of novel proprietary molecular cardiovascular therapeutics. NanoCor’s lead therapeutic is Carfostin®, an intracellular protein therapeutic for chronic heart failure (“CHF”). The technology incorporated in Carfostin® was developed at Mass General Hospital, the University of North Carolina at Chapel Hill, and the University of Cincinnati. NanoCor was the first company founded in the Asklepios BioPharmaceutical, Inc. (AskBio) portfolio of gene therapy companies, www.askbio.com.

 

Team

Sheila Mikhail, JD, MBA

Chief Executive Officer

Sheila Mikhail co-founded and was initial CEO of AskBio from 2002 through 2007. She left the company to become CEO of NanoCor Therapeutics, Inc., an AskBio spin-out. Most recently, Ms. Mikhail co-founded and was CEO of Bamboo Therapeutics, Inc., which in 20 months raised $50 million, advanced a therapeutic for GAN into the clinic, completed pre-IND studies for a Duchenne Muscular Dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016.

Trained as a lawyer, Ms. Mikhail practiced law for over 15 years, including a law firm that she founded, Life Sciences Law, which serviced clients such as Bayer, Gilead, GSK, Sanofi, and Aventis. She also practiced with Ropes and Gray in Boston. Ms. Mikhail earned a J.D., with honors, from Northwestern University; a finance M.B.A., with honors, from the University of Chicago; and a B.S., with highest honors, from the University of Illinois at Urbana-Champaign.

 

Roger J. Hajjar, MD

Chief Scientific Officer

Dr. Hajjar is a Co-founder and Chief Scientific Officer of NanoCor. Dr. Hajjar is an internationally renowned scientific leader in the field of cardiac gene therapy for heart failure. Dr Hajjar is the Director of the Cardiovascular Research Center and the Arthur & Janet C. Ross Professor of Medicine at the Icahn School of Medicine in New York, NY. He received his BS in biomedical engineering from Johns Hopkins University and his MD from Harvard Medical School and the Harvard-MIT Division of Health Sciences & Technology. He completed his training in internal medicine, cardiology and research fellowships at Massachusetts General Hospital in Boston. Dr. Hajjar served as Director of the Cardiovascular Laboratory of Integrative Physiology and Imaging at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Hajjar has also been a staff cardiologist in the Heart Failure & Cardiac Transplantation Center at Massachusetts General Hospital.

 

Ms. Rhonda L. Stanley

Chief Financial Officer

Ms. Rhonda L. Stanley has over 25 years of financial leadership experience in public and private companies. She previously served as the CFO of Bamboo Therapeutics, Inc. a privately held gene therapy company which was sold to Pfizer, Inc. in 2016. In addition, she has served as Corporate Controller and Treasurer of several publicly traded and venture-backed biotechnology companies including Nephrogenex, Inc (NASDAQ: NRX), Tranzyme, Inc. (NASDAQ: TZYM), Pozen Inc. (NASDAQ: POZN) and Aldagen, Inc.

Ms. Stanley has led several companies through an initial public offering including establishing public company reporting requirements and Sarbanes-Oxley compliance. She served as the Principal Financial and Accounting Officer of Tranzyme Inc. where she played an integral role in leading this international pharmaceutical company through a reverse merger with Ocera Therapeutics in 2013 (NASDAQ: OCRX). Ms. Stanley has an accounting degree from Bradley University, holds an M.B.A, and is a certified public accountant and a registered nurse. In addition, she has served as a Captain in the U.S. Army finance corp.

Board of Directors

Evangelia Kranias, PhD

Hanna Professor of Cardiology, Director of Cardiovascular Biology and Professor, Department of Pharmacology and Cell Biophysics, and Distinguished University Professor at the University of Cincinnati, Board Member, Scientific Founder

Jude Samulski, PhD

Director of the Gene Therapy Center at the University of North Carolina, Board Member, Scientific Founder

Sheila A. Mikhail, JD, MBA

Board Member, Founder